Therefore, the heterogeneity of PARP expression found in U87MG xenograft tumour may have resulted in the uneven uptake of [18F]olaparib, suggesting that tumour heterogeneity has a significant impact on the uptake of radiolabelled PARP inhibitors, including those used for radionuclide therapy. Here, PARP1 is linked to neoplasm.